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Abstract All decisions about initiating, continuing, or stop-
ping therapy of the hepatitis B virus (HBV) during pregnancy
must include an analysis of the risks and benefits for
mother and fetus. The trimester of the pregnancy and the
stage of the mother’s liver disease are important factors.
Treatment in the third trimester may be initiated to aid in
preventing perinatal transmission, which appears to be most
pronounced in mothers with high viral loads. Consideration
of initiating treatment in the third trimester should occur
after a high viral load is documented in the latter part of the
second trimester, to allow adequate time for initiation of
antiviral therapy with significant viral suppression before
delivery. This discussion should include the topic of
breastfeeding, because it is generally not recommended
while receiving antiviral therapy. Currently, lamivudine and
tenofovir appear to be the therapeutic options with the most
reasonable safety data in pregnancy.
Keywords Hepatitis B.Pregnancy.Perinatal
transmission.Treatment.Antiviral.Nucleoside.
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Introduction
It is estimated that 350 million to 400 million individuals
worldwide are chronically infected with the hepatitis B
virus (HBV) [1]. In regions with high prevalence, infection
is most commonly acquired through either perinatal or
horizontal transmission [2, 3]. The risk of progression to
chronic HBV infection is inversely proportional to the age
at which the infection was acquired. Without immunopro-
phylaxis, up to 90% of infants born to hepatitis B e antigen
(HBeAg)–positive mothers become infected. In contrast,
only 20% to 30% of children exposed between ages 1 and
5 years, and fewer than 5% of adults, become infected [4–
6]. Thus, women of childbearing age with chronic HBV
infection remain an important source for continued spread
of the virus.
This article addresses several issues pertinent to hepatitis
B therapy in pregnancy. First, the woman of childbearing
age who may require therapy for hepatitis B is discussed,
with particular emphasis on the timing of therapy, choice of
an agent, and the patient’s desire to have children in the
future. Second, an approach is outlined for the woman who
is newly diagnosed with hepatitis B early in pregnancy. In
addition, whether therapy should be continued, switched, or
stopped if an HBV-infected woman is on treatment and
becomes pregnant is debated. Finally, the question of
whether a pregnant woman should be treated in the third
trimester to help prevent perinatal transmission is addressed
in a proposed algorithm for the management of HBV in
pregnancy.
Therapy for HBV in Women of Childbearing Age
Seven therapies are approved by the US Food and Drug
Administration (FDA) for the treatment of hepatitis B,
includinginterferon(bothstandard and pegylated), lamivudine,
adefovir, entecavir, telbivudine, and tenofovir [3]. Factors that
influence treatment choice in women of childbearing age
include safety in pregnancy and breastfeeding, efficacy of
the agent, its barrier to resistance, and proposed length of
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it may be prudent to delay therapy until after the child is
born [7]. This approach requires a careful assessment of
the degree of hepatic activity and fibrosis, with either liver
biopsy or noninvasive methods. Although it is not used in
the pregnant woman, interferon can be used in the woman
of childbearing age, because therapy with this agent is for
a defined period (48 weeks) and often results in clinical
remission with HBeAg seroconversion [8]. This scenario
is in contrast to the oral antiviral agents that generally
require long-term therapy and result in much lower rates
of HBeAg seroconversion [3, 7].
For those who require therapy, it is advisable to discuss
the issue of pregnancy before starting treatment. A
“planned pregnancy” is preferable and may influence the
choice and timing of therapy, or potentially the timing of
pregnancy. In addition, given the relative paucity of
evidence for most recommendations, decisions about
treatment during pregnancy can be made with the luxury
of time for consideration of all relevant issues. Treatment
with tenofovir is an ideal choice, given its efficacy, high
barrier to resistance, and safety profile in pregnancy [9, 10].
Lamivudine, another agent that is considered safe in
pregnancy, has a high chance of emergence of resistant
virus with prolonged therapy and therefore is no longer a
first-line agent in the nonpregnant patient [3, 7, 10].
Newly Diagnosed Chronic HBV in Pregnancy
The pregnant woman who is newly diagnosed with HBV
early in pregnancy should undergo an assessment of her
infection. Decisions about initiating therapy in this setting
must include consideration of the risks and benefits for the
mother and the fetus. The risk-benefit equation also
depends upon the trimester of the pregnancy. The major
determinant of the need for HBV therapy for the mother is
the stage of her liver disease (both hepatic activity and
fibrosis) [7]. Treatment is generally recommended if the
mother is at risk of serious liver disease. Most women of
childbearing age are likely to have mild disease; therefore,
treatment can usually be postponed until after delivery.
Because many of these women are in the immune-tolerant
phase of infection (high HBV DNA levels with normal
alanine transaminase [ALT] and inactive liver biopsy),
therapy is generally not needed and no indication exists to
start therapy during the early stages of pregnancy [3, 7].
Therapy for Hepatitis B in Early Pregnancy
No antiviral agent has been approved by the FDA for use in
pregnancy. Thus, when a woman on HBV antiviral therapy
becomes pregnant, a decision needs to be made whether she
should continue therapy for the duration of the pregnancy
or if therapy should be withdrawn immediately. As with all
decisions during pregnancy, the health of the mother and
the fetus must be considered independently. From the
perspective of the fetus, the major concern is the risk of
exposure to medication during early embryogenesis. From
the perspective of the mother, the major issue is whether
stopping or changing medication will adversely affect both
short- and long-term liver disease outcomes. In general, if
the mother is known to have significant fibrosis, therapy
should be continued because the risk of flare with
withdrawal of therapy could result in decompensation of
her liver disease. This effect on the mother’s health could
also impact the health of the fetus.
All HBV antivirals are inhibitors of either nucleoside or
nucleotide polymerases. Although these drugs preferentially
target the RNA-dependent DNA polymerase of HBV, they
also interfere with replication of mitochondrial DNA, and this
can result in mitochondrial toxicity leading to the lactic
acidosissyndrome[11]. Although lactic acidosis syndrome is
very uncommon in adults, less is known about the potential
ramifications of mitochondrial toxicity in the developing
fetus. These effects may be more diverse, because toxicity
may affect organogenesis.
Safety data on HBV antivirals during pregnancy come
from two major sources: the Antiretroviral Pregnancy
Registry (APR) [10] and the Development of Antiretroviral
Therapy Study (DART) [12]. The APR is an international,
voluntary, prospective exposure registration cohort study of
women exposed to antiretroviral therapies, most of whom
are HIV-1 monoinfected. As of January 2010, data from
11,867 pregnancies were available. However, these data
included only 112 women with HBV monoinfection, in
whom birth defects were recorded in 2.7% of live births.
This statistic compares favorably to the 2.72% rate reported
by the Centers for Disease Control and Prevention (CDC)
birth defect surveillance system. Table 1 shows the number
of cases of early versus late exposure and the rate of birth
defects for each of the FDA-approved HBV antivirals. No
significant difference was reported in the rate of adverse
outcomes if the initial exposure of any HBV drug was in
the first trimester (2.7%) compared to the second or third
trimester (2.5%) of pregnancy. Although these data are
reassuring, it is important to look at the HBV agents
specifically. Lamivudine and tenofovir are the two agents
with the most in vivo experience in the first trimester and
appear to be safe. For telbivudine and entecavir, only 5 and
12 pregnancies with exposure in the first trimester are
recorded in the registry, with no adverse outcomes reported.
Although the APR is extremely useful, it has limitations,
including short follow-up and recording only defects
identified at birth. Developmental anomalies (eg, cardiac
198 Curr Hepatitis Rep (2010) 9:197–204or neurologic defects) identified at a later date may
therefore be omitted.
The DARTstudy is a 6-year, multicenter, randomized trial
of antiretroviral therapy among adults with symptomatic
HIV-1 infection or advanced disease/AIDS in Africa. The 3%
rate of congenital anomalies reported in this study also
compares favorably to the 2.72% reported by the CDC birth
defect surveillance system [12].
Continuing, Switching, or Discontinuing Therapy?
If the decision is made to continue HBV therapy during
pregnancy, the question then becomes whether the drug
should be replaced with an agent that has more in vivo
experience during pregnancy (ie, is thought to be “safer”).
For example, because safety data are lacking for entecavir,
and because it is an FDA pregnancy class C drug (Table 2),
switching to an alternate therapy should be strongly
considered [13]. If desired, the original treatment could
eventually be resumed after delivery. The two most
commonly used agents in pregnancy are lamivudine and
tenofovir. Lamivudine is also categorized as a class C agent
by the FDA because of reports of toxicity in rabbits with
first trimester exposure. However, because it was the first
oral agent approved for the treatment of HBV, extensive
clinical experience exists. The APR data also suggest that
lamivudine is safe despite its pregnancy C classification.
Although there is less clinical experience with tenofovir, it
is categorized as a class B agent by the FDA and has the
added benefit of a very high genetic barrier to resistance,
with no reported resistance identified to date [13, 14].
However, telbivudine, another class B agent, is seldom
used, for two reasons [13]. First, there is minimal in vivo
experience in pregnancy, and second, telbivudine has a low
barrier to resistance [15].
Rather than switching agents, withdrawal of treatment
for the duration of pregnancy may be preferable, especially
to the mother who wants to avoid any potential future risk
to the fetus. What would be the consequence to the mother
of stopping treatment completely? The natural history of
chronic HBV in pregnancy has not been well described.
Limited data exist to suggest that, rarely, severe complica-
tions of HBV occur late in pregnancy, with reports of liver
failure requiring liver transplantation in previously asymp-
tomatic individuals [16]. Data specifically addressing the
risk of stopping therapy during pregnancy are anecdotal.
Our knowledge of those risks relating to cessation of
therapy is derived from early clinical trials in nonpregnant
patients, with less advanced fibrosis. In these early studies,
Table 1 Antiretroviral pregnancy registry data
Agent Earliest trimester of exposure
1st trimester birth defects/live births 2nd/3rd trimester birth defects/live births
Lamivudine 99/3481 (2.8%) 130/5194 (2.5%)
Adefovir 0/37 0/0
Telbivudine 0/5 0/3
Tenofovir 19/879 (2.2%) 11/501 (2.2%)
Entecavir 0/12 0/2
Any HBV nucleoside/nucleotide 118/4414 (2.7%) 141/5700 (2.5%)
HBV—hepatitis B virus
Table 2 Food and drug administration pregnancy categories
Pregnancy
category A
Adequate and well-controlled human studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy
(and there is no evidence of risk in later trimesters)
Pregnancy
category B
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled
studies in pregnant women, or animal studies have shown an adverse effect, but adequate and well-controlled studies in
pregnant women have failed to demonstrate a risk to the fetus in any trimester
Pregnancy
category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled
studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
Pregnancy
category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience
or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
Pregnancy
category X
Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk
based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in
pregnant women clearly outweigh potential benefits
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patients who remained HBeAg-positive. Follow-up con-
firmed that HBV DNA levels rebounded, but rarely did this
rebound result in clinically significant flares of hepatitis
[17, 18]. In contrast, in those patients with severe fibrosis or
cirrhosis at baseline, flares upon treatment withdrawal can
result in decompensation [19].
Overall, it appears the risk of an adverse outcome with
continuing antiviral therapy during pregnancy is likely very
low. However, therapy could be discontinued with close
observation of the mother to avoid continued fetal exposure
during the first trimester, especially in the patient who does
not have advanced fibrosis.
Rationale for Treatment in the Third Trimester
The majority of perinatal transmission is thought to occur at
delivery, because a combination of passive immunization
with hepatitis B immunoglobulin (HBIG) given within 12 h
of birth and active immunization with three doses of the
hepatitis B vaccine in the first 6 months of life resulted in
preventing most infections in this setting. Early seminal
studies by Beasley et al. [20, 21] showed that HBIG
administration could reduce the rate of HBV transmission
from more than 90% from HBeAg-positive mothers down
to about 26%. When combined with the vaccine, the rates
of transmission fell to 3% to 7% [22, 23]. When one looks
at the vaccine and HBIG failures, almost all occur in
HBeAg-positive women with very high viral loads,
generally above 10
8 copies/mL [24]. A recent report
suggested an overall 3% perinatal transmission rate in
viremic mothers despite the use of immunoprophylaxis
[25￿]. The rate was as high as 7% in viremic HBeAg-
positive mothers and 9% in those mothers who had viral
loads greater than 10
8 copies/mL. This finding raises the
question of whether antiviral therapy before delivery would
lower the viral load adequately to prevent transmission.
Evidence for Treatment in the Third Trimester
Should pregnant women who are HBsAg-positive and
highly viremic receive antiviral therapy in the third
trimester to prevent perinatal transmission? No consensus
on this issue has yet been reached [7]. The principal of
treatment late in pregnancy to prevent or reduce the rate of
perinatal transmission has been established with other
viruses. In HIV-infected mothers, the effect of antiretroviral
agents (including lamivudine) on the reduction of mother-
to-child transmission of HIV was shown to be efficacious
[26]. Antivirals have also been advocated late in pregnancy
to prevent acquisition of neonatal herpes [27].
In a pilot study, eight women with HBV DNA levels
greater than 10
9 copies/mL were given lamivudine at
34 weeks of gestation. Babies were vaccinated and received
HBIG at birth, and only one became infected, compared to
7 of 25 (28%) cases of transmission in a matched historical
control population [28]. This finding led to a randomized,
double-blind, placebo-controlled trial of lamivudine to
prevent transmission in highly viremic HBeAg-positive
women [29￿]. At 1 year of age, 18% of babies of
lamivudine-treated mothers were HBsAg-positive com-
pared to 39% in the placebo-treated arm. Both groups
received vaccination and HBIG. Based on these results, the
authors recommended treatment in the third trimester for
women with high viral loads. Unfortunately, because of
major problems with loss to follow-up, the data are
extremely hard to interpret. At 1 year, 13% of babies in
the lamivudine arm and 31% in the placebo arm were lost
to follow-up. Evaluating only those with complete data,
there was a trend but no significant difference in the rate of
HBsAg positivity at 1 year (6% lamivudine vs 12%
placebo, P=0.37). The study was also underpowered
(power=53%), because of slow recruitment. No conse-
quences were reported to mother or baby with lamivudine
treatment in the study. More recently, a meta-analysis was
reported to evaluate the efficacy of lamivudine in reducing
in utero transmission of HBV [30￿]. A total of 10
randomized controlled trials (RCTs) examining 951 HBV-
carrier mothers were included [29￿, 31–39]. The RCTs
evaluated included newborns who received immunopro-
phylaxis at birth and women who were treated with
lamivudine from 24 to 32 weeks of gestation, until delivery
to 1 month post-delivery. Newborns in the lamivudine
group had a 13% to 24% significantly lower incidence of
intrauterineexposure,indicatedbynewbornHBsAg(P=0.04)
and HBV DNA (P<0.001) positivity. In addition, newborns
in the lamivudine treated group had a 1.4% to 2% lower
perinatal infection rate at 9 to 12 months, as indicated by
HBsAg (P<0.01) and HBV DNA (P<0.001) seropositivity.
This report was limited by the quality of the studies included
(most studies were only rated 3 of 5 on the Jadad scale [40])
and the heterogeneity of the definition used for high viral
load that prompted therapy.
In a recent study of 31 pregnant women in China,
treatment with telbivudine was commenced between 28 and
32 weeks and was continued to 30 days postpartum [41].
Compared with 30 pregnant patients who did not receive
therapy and had similar viral loads at baseline and at
parturition, the viral loads in the patients treated with
telbivudine were reduced significantly, from 7.38 log10 at
baseline to 4.08 log10 prior to parturition (P<0.01). All
babies received active and passive immunoprophylaxis.
The infection rate was 0% in those treated with telbivudine
and 13.3% in the untreated controls.
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area. However, given its potency, tenofovir would be
expected to be at least equally as effective as lamivudine
in reducing perinatal transmission. This characteristic,
together with its high barrier to resistance, makes it an
attractive agent to consider in the third trimester.
Although treatment in the third trimester would be
anticipated to result in a significant lowering of the viral
load (which would help prevent perinatal transmission), this
result has not been clearly shown and remains controver-
sial. In addition, although a high viral load is clearly
important, it is not the only factor predisposing to failure of
immunoprophylaxis. This is highlighted by a case in which
a child developed chronic HBV infection, despite suppres-
sion of HBV DNA to undetectable levels in the mother with
lamivudine therapy throughout gestation and appropriate
immunoprophylaxis after birth [42]. Rarely, infection may
occur in utero, particularly in the setting of threatened
preterm labor with very high maternal viral loads [43].
Furthermore, long-term safety data are lacking, and potential
risks to the mother include the development of antiviral
resistance (relatively unlikely, given the short duration of
therapy) and flare of hepatitis after treatment withdrawal. In
one study, 42% of those who did not receive antiviral therapy
during pregnancy experienced a flare in the postpartum
period, compared to 62% among those who had been treated
and then discontinued therapy at delivery [44].
Algorithm for Management of HBV in the Pregnant
Patient
An algorithm for the management and treatment of HBV in
pregnancy is proposed in Fig. 1. Routine antepartum care
Fig. 1 An algorithm for
management of hepatitis B virus
(HBV) in the pregnant patient.
ALT—alanine transaminase;
HBcAb—hepatitis B core antibody
(total); HBeAb—hepatitis B e
antibody; HBeAg—hepatitis B
e antigen; HBsAb—hepatitis B
surface antibody; HBsAg—hepatitis
B surface antigen
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hepatitis B in the first trimester. If she is negative, her child
will be vaccinated at birth. The mother does not have to be
vaccinated during pregnancy, although it is considered safe
and should therefore be administered to those with high-
risk behavior for acquisition.
For those who test positive early in pregnancy, an
assessment of the mother’s HBV status should occur,
including a hepatic panel, HBV serologies, and platelet
count. If the patient has very active HBV (significantly
elevated ALT with a high viral load), or if cirrhosis is
suspected (low platelet count or suggestive imaging), then
therapy should be initiated regardless of trimester. However,
if therapy is not warranted (inactive disease with low ALT
and low viral load), continued surveillance is suggested
because pregnancy can result in a flare of hepatitis B,
later in pregnancy and for several months postpartum
[16, 44].
Subsequently, it is recommended that all women have
their HBV DNA viral load quantified toward the end of the
second trimester (at 26–28 weeks gestation) so that a final
decision regarding therapy can occur shortly thereafter. This
assessment will allow enough time in the third trimester to
significantly drop the viral load after therapy is initiated to
decrease the perinatal transmission rate. Women with high
viral loads (>10
7 copies/mL) should consider initiating
therapy early in the third trimester (28–30 weeks), after a
thorough discussion of the risks and benefits, because data
are too limited to mandate therapy. Once started, therapy is
continued for the duration of the pregnancy and can be
discontinued postpartum if desired. The decision to
discontinue therapy is often influenced by the woman’s
desire for subsequent pregnancies. The timing of therapy
discontinuation postpartum remains unclear. In published
studies, therapy is discontinued anywhere from birth to
1 month after delivery [30￿]. In practice, therapy is often
continued up to 6 months postpartum. Regardless of when
therapy is discontinued, a small but real risk of flare exists,
and the mother should be monitored closely after withdraw-
al for at least 6 months. Another factor that may influence
the timing of treatment discontinuation postpartum is the
mother’s desire to breastfeed. Few data are available
regarding the safety of breastfeeding while on antiviral
therapy; thus, breastfeeding while on treatment for HBV is
not recommended [45, 46].
When deciding on therapy in the third trimester, the
perinatal transmission outcome of prior pregnancies must
be considered. If previous pregnancies did not result in
perinatal transmission, then a viral load of greater than 10
7
copies/mL should be used to determine if therapy should be
initiated (similar to the woman who has had no previous
children). However, if perinatal transmission did occur with
a prior pregnancy, then the risk of perinatal transmission in
the current pregnancy is likely higher [7]. In such cases,
strong consideration for initiating therapy in the third
trimester is recommended, regardless of the mother’s viral
load at the end of the second trimester.
Transmission of HBV Infection in Breastfed Babies
Although early studies claimed that HBV transmission
could occur through breast milk, more recent studies
have shown similar rates of acquisition, regardless of
whether babies were fed with breast milk or formula. In
1975, before the availability of neonatal immunization,
the rates of acquisition of HBV were found to be 53% in
breast-fed and 60% in formula-fed babies born to
HBsAg-positive mothers [47]. These data are limited
because the high vertical transmission rates confounded
t h et r u er a t eo fa c q u i s i t i o nf rom breastfeeding. After the
introduction of immunoprophylaxis, Hill et al. [48] found
a similar rate of infection in breast-fed and formula-fed
infants (0% and 3%). Thus, current guidelines state that
breastfeeding is not contraindicated in HBV-infected
mothers who are not on antiviral therapy whose infants
receive immunoprophylaxis [3].
For mothers on antiviral therapy, breastfeeding is not
recommended. According to prescribing information, it
has not been recommended that women breastfeed their
infants while taking lamivudine or tenofovir, to avoid
risking postnatal transmission of HIV-1 infection [45,
46]. Although it is known that lamivudine and tenofovir
are both excreted into human breast milk, little is known
about the extent of exposure of antiviral agents during
breastfeeding. Thus,littleisknownabouttheoverallsafetyof
breastfeeding in this setting.
Conclusions
Factors to consider when deciding whether HBV therapy is
warranted for either the woman of childbearing age or the
pregnant woman include extent of existing liver disease,
efficacy, and safety of existing FDA-approved antiviral
agents. Although none of these agents are approved for use
in this setting, data are emerging regarding safety. With
increasing data, fewer delays occur in treating pregnant
women who have clinically active disease. However, it
remains unclear if therapy is beneficial when initiated in the
third trimester in highly viremic mothers. Additional studies
are needed to address this question.
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